| P50 | author | Elizabeth Powell | Q42597946 |
| | Kelly L Hayward | Q56984142 |
| | Katharine M Irvine | Q61248154 |
| | Patricia C Valery | Q62933394 |
| | Preya J Patel | Q89597239 |
| P2093 | author name string | William Rosenberg | |
| | Suzanne Williams | |
| | Nivene Saad | |
| | Anne Bernard | |
| | Tracey Johnson | |
| | Guy Lampe | |
| | Lyndall Buck | |
| | Andrew Donald Clouston | |
| | Anthony William Russell | |
| | Fabrina Hossain | |
| | Katherine Anne Stuart | |
| | Leigh Ula Horsfall | |
| | Nigel Neil Brown | |
| | Xuan Banh | |
| P2860 | cites work | Treatment of patients with type 2 diabetes and non-alcoholic fatty liver disease: current approaches and future directions | Q26751258 |
| | Transient elastography (FibroScan(®)) with controlled attenuation parameter in the assessment of liver steatosis and fibrosis in patients with nonalcoholic fatty liver disease - Where do we stand? | Q28079445 |
| | Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European Liver Fibrosis Panel and exploring simple markers | Q28258678 |
| | Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO Collaborative Project on Early Detection of Persons with Harmful Alcohol Consumption--II | Q28260514 |
| | Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies | Q29614505 |
| | Design and validation of a histological scoring system for nonalcoholic fatty liver disease | Q29614930 |
| | Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis | Q30238749 |
| | Metabolic syndrome--a new world-wide definition. A Consensus Statement from the International Diabetes Federation | Q34567335 |
| | Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease | Q35893923 |
| | Cirrhosis is under-recognised in patients subsequently diagnosed with hepatocellular cancer | Q36547364 |
| | Direct comparison of the FibroScan XL and M probes for assessment of liver fibrosis in obese and nonobese patients | Q37636503 |
| | Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis | Q38090905 |
| | The Diagnosis and Management of Nonalcoholic Fatty Liver Disease: Practice Guidance from the American Association for the Study of Liver Diseases. | Q38676257 |
| | Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. | Q38680300 |
| | Clinical patterns of hepatocellular carcinoma in nonalcoholic fatty liver disease: A multicenter prospective study | Q38939495 |
| | Presence of diabetes mellitus and steatosis is associated with liver stiffness in a general population: The Rotterdam study. | Q38985095 |
| | Using non-invasive biomarkers to identify hepatic fibrosis in people with type 2 diabetes mellitus: the Edinburgh type 2 diabetes study. | Q39253135 |
| | Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the U.S. | Q39283211 |
| | The Asia-Pacific Working Party on Nonalcoholic Fatty Liver Disease Guidelines 2017 Part 1: Definition, risk factors and assessment | Q39410610 |
| | Feasibility of liver stiffness measurement in morbidly obese patients undergoing bariatric surgery using XL probe. | Q39679345 |
| | Transient elastography for the diagnosis of liver fibrosis | Q39820612 |
| | Cirrhosis Patients with Nonalcoholic Steatohepatitis Are Significantly Less Likely to Receive Surveillance for Hepatocellular Carcinoma | Q40214331 |
| | Screening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements: a prospective cohort study | Q41073361 |
| | Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States | Q41626076 |
| | ELF score ≥9.8 indicates advanced hepatic fibrosis and is influenced by age, steatosis and histological activity | Q42177206 |
| | Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up | Q42201783 |
| | Mortality from chronic liver diseases in diabetes | Q42215005 |
| | Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease. | Q42923153 |
| | Discordance in fibrosis staging between liver biopsy and transient elastography using the FibroScan XL probe | Q43489886 |
| | Awareness and opinions of non-alcoholic fatty liver disease by hospital specialists | Q43489996 |
| | Presence and severity of non-alcoholic fatty liver disease in a large prospective primary care cohort. | Q43565987 |
| | The utility of radiological imaging in nonalcoholic fatty liver disease. | Q44116674 |
| | The Enhanced Liver Fibrosis (ELF) score: normal values, influence factors and proposed cut-off values | Q44513485 |
| | Performance characteristics of vibration-controlled transient elastography for evaluation of nonalcoholic fatty liver disease | Q45066338 |
| | Alcohol Consumption in Diabetic Patients with Nonalcoholic Fatty Liver Disease. | Q46809187 |
| | Underappreciation of non-alcoholic fatty liver disease by primary care clinicians: limited awareness of surrogate markers of fibrosis. | Q47627120 |
| | Concomitant screening for liver fibrosis and steatosis in French type 2 diabetic patients using Fibroscan | Q47849653 |
| | Liver stiffness in nonalcoholic fatty liver disease: A comparison of supersonic shear imaging, FibroScan, and ARFI with liver biopsy | Q47942345 |
| | Non-invasive algorithm of enhanced liver fibrosis and liver stiffness measurement with transient elastography for advanced liver fibrosis in chronic hepatitis B. | Q51139539 |
| | Non-invasive assessment of liver fibrosis with transient elastography (FibroScan®): applying the cut-offs of M probe to XL probe. | Q51192690 |
| | Enhanced Liver Fibrosis (ELF) test accurately identifies liver fibrosis in patients with chronic hepatitis C. | Q51717108 |
| | Non-alcoholic fatty liver disease (NAFLD): summary of NICE guidance | Q56002223 |
| | Feasibility and diagnostic performance of the FibroScan XL probe for liver stiffness measurement in overweight and obese patients | Q57735452 |
| | EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease | Q60462090 |
| | Diagnosis of liver fibrosis and cirrhosis using liver stiffness measurement: comparison between M and XL probe of FibroScan® | Q82980218 |
| | Pathologic criteria for nonalcoholic steatohepatitis: interprotocol agreement and ability to predict liver-related mortality | Q83500394 |
| | ARFI, FibroScan, ELF, and their combinations in the assessment of liver fibrosis: a prospective study | Q83947864 |
| | Liver stiffness measurement using XL probe in patients with nonalcoholic fatty liver disease | Q87406034 |
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | metabolic dysfunction–associated steatotic liver disease | Q1546498 |
| | fatty liver disease | Q6058862 |
| P304 | page(s) | 893-905 | |
| P577 | publication date | 2018-08-06 | |
| P1433 | published in | Hepatology Communications | Q50817751 |
| P1476 | title | A Pragmatic Approach Identifies a High Rate of Nonalcoholic Fatty Liver Disease With Advanced Fibrosis in Diabetes Clinics and At-Risk Populations in Primary Care | |
| P478 | volume | 2 | |